Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Oct:91:153671.
doi: 10.1016/j.phymed.2021.153671. Epub 2021 Jul 17.

Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial

Jia Liu  1 , Wei Yang  1 , Yue Liu  2 , Cheng Lu  1 , Lianguo Ruan  3 , Chen Zhao  1 , Ruili Huo  4 , Xin Shen  5 , Qing Miao  2 , Wenliang Lv  6 , Hao Li  2 , Huaxin Shi  4 , Lijie Hu  4 , Zhixu Yang  2 , Li Zhang  2 , Bing Wang  2 , Guoju Dong  2 , Yongyue Xian  2 , Bin Li  2 , Zhenqi Zhou  2 , Chunyan Xu  2 , Yingying Chen  2 , Yongjun Bian  6 , Jing Guo  6 , Jinliang Yang  6 , Jian Wang  6 , Wensheng Qi  6 , Suping Chen  6 , Yang Chen  6 , Bei Yan  6 , Wei Wang  6 , Jing Li  2 , Xiaolei Xie  2 , Ming Xu  2 , Jianxin Jiang  2 , Gang Wang  2 , Xiaodong Cong  2 , Haoning Zhu  2 , Jiaheng Shi  6 , Luxing Leng  6 , Dongxu Li  6 , Lanping Guo  7 , Luqi Huang  8
Affiliations
Randomized Controlled Trial

Combination of Hua Shi Bai Du granule (Q-14) and standard care in the treatment of patients with coronavirus disease 2019 (COVID-19): A single-center, open-label, randomized controlled trial

Jia Liu et al. Phytomedicine. 2021 Oct.

Abstract

Objective: To evaluate the efficacy and safety of Hua Shi Bai Du Granule (Q-14) plus standard care compared with standard care alone in adults with coronavirus disease (COVID-19).

Study design: A single-center, open-label, randomized controlled trial.

Setting: Wuhan Jinyintan Hospital, Wuhan, China, February 27 to March 27, 2020.

Participants: A total of 204 patients with laboratory-confirmed COVID-19 were randomized into the treatment group and control group, consisting of 102 patients in each group.

Interventions: In the treatment group, Q-14 was administered at 10 g (granules) twice daily for 14 days, plus standard care. In the control group, patients were provided standard care alone for 14 days.

Main outcome measure: The primary outcome was the conversion time for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral assay. Adverse events were analyzed in the safety population.

Results: Among the 204 patients, 195 were analyzed according to the intention-to-treat principle. A total of 149 patients (71 vs. 78 in the treatment and control groups, respectively) tested negative via the SARS-CoV-2 viral assay. There was no statistical significance in the conversion time between the treatment group and control group (Full analysis set: Median [interquartile range]: 10.00 [9.00-11.00] vs. 10.00 [9.00-11.00]; Mean rank: 67.92 vs. 81.44; P = 0.051). The recovery time for fever was shorter in the treatment group than in the control group. The disappearance rate of symptoms like cough, fatigue, and chest discomfort was significantly higher in the treatment group. In chest computed tomography (CT) examinations, the overall evaluation of chest CT examination after treatment compared with baseline showed that more patients improved in the treatment group. There were no significant differences in the other outcomes.

Conclusion: The combination of Q-14 and standard care for COVID-19 was useful for the improvement of symptoms (such as fever, cough, fatigue, and chest discomfort), but did not result in a significantly higher probability of negative conversion in the SARS-CoV-2 viral assay. No serious adverse events were observed.

Trial registration: ChiCTR2000030288.

Keywords: COVID-19; Chinese medicine; Hua Shi Bai Du Granule; Randomized Controlled Trial; efficacy; safety.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Fig. 1
Fig. 1
Research flow chart
Fig. 2
Fig. 2
Time to conversion analysis of SARS-CoV-2 viral assay and conversion ending (n = 149, FAS)
Fig. 3
Fig. 3
Time to conversion analysis of SARS-CoV-2 viral assay and conversion ending (n = 148, PPS)
Fig. 4
Fig. 4
Time to conversion analysis of SARS-CoV-2 viral assay and conversion ending, in participants with cardiovascular disease who reached negative conversion (n = 116)
Annex 1
Annex 1
Research Period
Annex 2
Annex 2
Symptom improvement-FAS
Annex 3
Annex 3
Symptom improvement-PPS
See this image and copyright information in PMC

References

    1. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of Chest CT and RT-PCR Testing for Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020;296:E32–E40. doi: 10.1148/radiol.2020200642. - DOI - PMC - PubMed
    1. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q., 2020. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ368, m1091. doi: 10.1136/bmj.m1091. - PMC - PubMed
    1. Elhadi M, Msherghi A, Elgzairi M, Alhashimi A, Bouhuwaish A, Biala M, Abuelmeda S, Khel S, Khaled A, Alsoufi A, Elmabrouk A, Alshiteewi FB, Alhadi B, Alhaddad S, Gaffaz R, Elmabrouk O, Hamed T.B., Alameen H, Zaid A, Elhadi A, Albakoush A. Psychological status of healthcare workers during the civil war and COVID-19 pandemic: A cross-sectional study. J. Psychosom. Res. 2020;137 doi: 10.1016/j.jpsychores.2020.110221. - DOI - PMC - PubMed
    1. GolemiMinga I, Golemi L, Tafur A, Pursnani A. The Novel Coronavirus Disease (COVID-19) and Its Impact on Cardiovascular Disease. Cardiol. Rev. 2020;28:163–176. doi: 10.1097/CRD.0000000000000317. - DOI - PubMed
    1. Hu K, Guan W.J., Bi Y, Zhang W, Li L, Zhang B, Liu Q, Song Y, Li X, Duan Z, Zheng Q, Yang Z, Liang J, Han M, Ruan L, Wu C, Zhang Y, Jia ZH, Zhong NS. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine. 2020 doi: 10.1016/j.phymed.2020.153242. - DOI - PMC - PubMed

Publication types